Immune Response News and Research

RSS

Research on sheep population could help explain variation in vaccine protection

Strong immunity may play a key role in determining long life, but may do so at the expense of reduced fertility, a Princeton University study has concluded.

29 Oct 2010

Antigenics third quarter net loss decreases from $10.8 million to $5.9 million

Antigenics Inc. reported today its results for the quarter ended September 30, 2010. The company incurred a net loss attributable to common stockholders of $5.9 million, or $0.06 per share, basic and diluted, for the third quarter of 2010, compared with a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, in the third quarter of 2009.

28 Oct 2010

New findings suggest way to treat lung diseases

A new study of an exotic, infectious virus that has caused three recent outbreaks in the United States reveals clues to how the virus might damage lungs during infection. The findings also suggest possible new ways to treat lung diseases in humans.

28 Oct 2010

Sex hormones behind increased risk of destructive periodontitis in men

Sex hormones may be the biological reason why men are at greater risk than women for destructive periodontitis, an infection of the gums, according to researchers at the University of Maryland Dental School.

27 Oct 2010

Bivalent oral polio vaccine produces better immune response than more commonly used trivalent vaccine, study says

The bivalent oral polio vaccine (bOPV) was found to induce a significantly higher immune response than the existing trivalent oral polio vaccine (tOPV), according to a study published on Tuesday in the journal Lancet, Reuters reports.

27 Oct 2010

Jamieson releases flu-fighting formula with echinacea

Jamieson Laboratories, Canada's largest manufacturer of advanced natural-health products, announced the release of FluShield™, a clinically proven flu-fighting formula that is made with a patented, next-generation echinacea extract known as LPx3.

27 Oct 2010

Viral microRNA allows EBV to hide within cells and evade immune system

While most commonly associated with mononucleosis, Epstein-Barr virus (EBV) has been linked to many diseases that affect people long after the initial infection takes place, including some forms of cancer. In the current issue of the Journal of Biological Chemistry, scientists at The Wistar Institute describe how viral microRNA - small segments of RNA that suppress the effects of gene activity - allows EBV to hide within cells and evade the immune system.

26 Oct 2010

Antigenics expands HSPPC-96 Phase 2 clinical study in glioma

Antigenics, Inc. today announced the expansion of a phase 2 clinical study of HSPPC-96 (Oncophage® vaccine; vitespen), Antigenics' personalized therapeutic cancer vaccine, in patients with newly diagnosed glioma.

25 Oct 2010

FlexBone shows potential replacement for current bone transplantations

With a failure rate as high as 50 percent, bone tissue grafts pose a significant obstacle to orthopedic surgeons attempting to repair complex fractures or large areas of bone loss, such as those often caused by trauma and cancer. Current synthetic substitutes rarely possess the bone-like properties needed for successful grafting and are often difficult for surgeons to manipulate in the operating room. In response to these challenges, researchers at UMass Medical School have developed an easy-to-produce, inexpensive, synthetic bone material called FlexBone.

25 Oct 2010

Altogen Biosystems releases PEG-Liposome siRNA In Vivo Transfection Kit

Altogen Biosystems announced the release of its second generation of in vivo RNAi transfection reagent in the company's popular in vivo delivery product line: PEG-Liposome siRNA In Vivo Transfection Kit. This reagent is also compatible for in vivo transfection of other negatively charged molecules – RNA, DNA, and small proteins.

22 Oct 2010

Scientists discover new cell that may limit inflammation in CNS

Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.

22 Oct 2010

NIH awards three new SBIR grants to Taiga

Taiga Biotechnologies, Inc. today announced that the company has received three new Small Business Innovation Research (SBIR) grants from the National Institutes of Health, totaling $1.7 million. This adds to the two previous grants awarded to Taiga for various applications of its proprietary technology platforms, for a total in NIH funding to date of over $2.1 million.

22 Oct 2010

Protein IL-37 could help treat inflammatory diseases in adults and children

A husband and wife research team from Melbourne, Australia, have identified a protein that may be a key therapy for many inflammatory diseases, including those affecting premature babies.

21 Oct 2010

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

Intercell AG and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug, nitazoxanide, during the first half of 2011.

21 Oct 2010

LSUHSC receives NIH grant for research on cancer and infectious diseases

LSU Health Sciences Center New Orleans has been awarded $12 million over five years by the National Institutes of Health to conduct research on diseases like prostate and stomach cancers, lymphoma and leukemia, dengue fever, tuberculosis, and herpes infections, as well as to support the development of academic research scientists.

21 Oct 2010

Valensa enters agreement with Mercola for Flex Pro ES formulation

Valensa International and Mercola Health Resources, LLC announced today that they have entered into a license and supply agreement that provides Mercola Health Resources with Valensa's new Flex Pro ES(TM) joint health formulation.

21 Oct 2010

SHIP and PTEN enzymes act cooperatively to suppress B cell lymphoma: Study

Lymphoma is a cancer of the immune system. White blood cells divide again and again, spreading abnormally throughout the body. Lymphomas can arise from two types of white blood cells, T cells or B cells, which divide uncontrollably when the molecular mechanisms that keep them in check go awry.

20 Oct 2010

MannKind begins MKC1106-MT Phase 2 trial for advanced melanoma

MannKind Corporation today announced the first patient has been dosed in a phase 2 clinical trial of the novel, investigational cancer vaccine MKC1106-MT. As a part of MannKind's cancer immunotherapy program, this phase 2 study will evaluate the safety, tolerability, immune response and clinical response of MKC1106-MT in patients with advanced melanoma.

20 Oct 2010

Jefferson researchers progress in understanding mechanism behind systemic fibrotic disorder

Scientists from the Jefferson Institute of Molecular Medicine of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for MRI. Two of their studies on the disorder appear together in the November issue of the Annals of Rheumatic Diseases.

20 Oct 2010

New clinical trial to treat brain cancer launched

Cancer Research UK and Cancer Research Technology the charity's development and commercialisation arm together with immatics biotechnologies have launched the first clinical trial of a promising cancer vaccine to treat glioblastoma, one of the most common forms of brain cancer.

19 Oct 2010